Literature DB >> 3299095

Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

W E Dismukes, G Cloud, H A Gallis, T M Kerkering, G Medoff, P C Craven, L G Kaplowitz, J F Fisher, C R Gregg, C A Bowles, S Shadomy, A M Stamm, R B Diasio, L Kaufman, S Soong, W C Blackwelder.   

Abstract

One hundred ninety-four patients with cryptococcal meningitis were enrolled in a multicenter, prospective, randomized clinical trial to compare the efficacy and toxicity of four as compared with six weeks of combination amphotericin B and flucytosine therapy. Among 91 patients who met preestablished criteria for randomization, cure or improvement was noted in 75 percent of those treated for four weeks and in 85 percent of those treated for six weeks. The estimated relapse rate for the four-week regimen was higher--27 as compared with 16 percent--whereas the incidence of toxic effects for the two regimens was similar--44 as compared with 43 percent. Among 23 transplant recipients, 4 of 5 treated for four weeks relapsed, leading to the decision to treat the rest of the group for six weeks. Only 3 of the 18 treated for six weeks relapsed. In a third group of 80 patients, the protocol was not followed during the initial four weeks, and these patients were not randomized. Thirty-eight died or relapsed. Multifactorial analysis of pretreatment factors for all 194 patients identified three significant predictors (P less than 0.05) of a favorable response: headache as a symptom, normal mental status, and a cerebrospinal fluid white-cell count above 20 per cubic millimeter. These and other findings in this study are consistent with the view that the four-week regimen should be reserved for patients who have meningitis without neurologic complications, underlying disease, or immunosuppressive therapy; a pretreatment cerebrospinal fluid white-cell count above 20 per cubic millimeter and a serum cryptococcal antigen titer below 1:32; and at four weeks of therapy, a negative cerebrospinal fluid India ink preparation and serum and cerebrospinal fluid cryptococcal-antigen titers below 1:8. Patients who do not meet these criteria should receive at least six weeks of therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3299095     DOI: 10.1056/NEJM198708063170602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  73 in total

1.  Efficacy of SCH39304 in murine cryptococcosis.

Authors:  B I Restrepo; J Ahrens; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  Chronic Meningitis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

Review 3.  Antifungal therapy: from amphotericin B to present.

Authors:  W E Dismukes
Journal:  Trans Am Clin Climatol Assoc       Date:  1993

4.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

5.  Cryptococcal cerebrospinal fluid shunt infection treated with fluconazole.

Authors:  D Eymard; F Lebel
Journal:  Can J Infect Dis       Date:  1993-07

6.  Use of fluconazole in the treatment of non-AIDS cryptococcal meningitis.

Authors:  S J Antony; A Patel; J Leonard
Journal:  J Natl Med Assoc       Date:  1997-10       Impact factor: 1.798

7.  Combination antifungal therapy for the treatment of invasive yeast and mold infections.

Authors:  John W Baddley; Peter G Pappas
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

Review 8.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 9.  Amphotericin B: current understanding of mechanisms of action.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

10.  History of medical mycology in the united states.

Authors:  A Espinel-Ingroff
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.